What is Obatala Sciences?
Obatala Sciences operates at the intersection of life sciences manufacturing and advanced biomedical research. The company specializes in the production of human-derived hydrogels, stem cells, and functional Fat-on-a-chip models, which are instrumental in pre-clinical drug development. By providing researchers with more accurate, human-centric biological models, Obatala Sciences addresses the persistent challenges in metabolic disease research and the translation of laboratory findings into successful clinical trials. Their product portfolio, including the ObaCell line, is designed to bridge the gap between basic research and therapeutic application, ultimately aiming to foster more equitable and effective patient outcomes globally.
How much funding has Obatala Sciences raised?
Obatala Sciences has raised a total of $3.1M across 2 funding rounds:
Debt
$92K
Series A
$3M
Debt (2021): $92K with participation from PPP
Series A (2022): $3M led by être Venture Capital, Benson Capital Partners, Hackett Robertson Tobe Group, Elevate Capital Fund, and Ochsner Lafayette General Healthcare Innovation Fund
Key Investors in Obatala Sciences
Hackett Robertson Tobe Group
An independent institutional investment consulting firm and registered Investment Adviser providing customized counsel to public funds, retirement plan sponsors, and private entities with a focus on sustainable and equitable solutions.
Benson Capital Partners
A New Orleans-based firm operating within the investment banking sector, providing strategic financial support to emerging companies.
être Venture Capital
A venture capital firm focused on identifying and supporting high-growth potential companies within the innovation and technology sectors.
What's next for Obatala Sciences?
With the recent influx of capital, Obatala Sciences is poised to scale its manufacturing capabilities and expand its footprint in the global drug development market. The strategic focus will likely center on deepening the integration of its biomaterials into high-throughput screening environments, thereby reducing the time and cost associated with preclinical testing. As the company moves forward, the emphasis will remain on refining its proprietary hydrogel technology and expanding its service offerings to support pharmaceutical partners in navigating the complexities of clinical trial preparation. This phase of growth is expected to solidify the company's position as a leader in the development of next-generation, human-relevant research tools.
See full Obatala Sciences company page
